NeuroVive's Partner Yungjin Pharm Completes KL1333 Phase I Study Recruitment |
| April 17, 2018 | April 2018 Bond Updates |
|
LUND, Sweden, April 17, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today announced that the last visit of the last healthy volunteer in the clinical phase I single... |
| View more at: https://www.prnewswire.com/news-releases/neurovives-partner-yungjin-pharm-completes-kl1333-phase-i-study-recruitment-300631003.html |
| Related News |